You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,895,001


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,895,001
Title:Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.
Inventor(s): Moyo; Victor (Concord, MA), Garcia; Gabriela (Roslindale, MA)
Assignee: Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/583,949
Patent Claims:1. A method of treating triple negative breast cancer which expresses ErbB3, the method comprising: identifying a patient with a triple negative breast cancer tumor, and administering to the identified patient an effective amount of an anti-cancer agent comprising an anti-ErbB3 antibody that comprises, in amino terminal to carboxy terminal order, a V.sub.H CDR1 sequence as shown in SEQ ID NO:3, a V.sub.H CDR2 sequence as shown in SEQ ID NO:4 and a V.sub.H CDR3 sequence as shown in SEQ ID NO:5, and, in amino terminal to carboxy terminal order, a V.sub.L CDR1 sequence as shown in SEQ ID NO:6, a V.sub.L CDR2 sequence as shown in SEQ ID NO:7 and a V.sub.L CDR3 sequence as shown in SEQ ID NO:8.

2. The method of claim 1, wherein the administration of the effective amount of the anti-cancer agent suppresses growth of the triple negative breast cancer tumor.

3. The method of claim 1, wherein the anti-ErbB3 antibody is an antibody comprising a VH sequence as shown in SEQ ID NO:1 and a VL sequence as shown in SEQ ID NO:2.

4. The method of claim 1, wherein identifying the patient includes histopathologically characterizing the breast cancer tumor as having a basal-like phenotype.

5. The method of claim 1, wherein identifying the patient includes histopathologically characterizing the breast cancer tumor as having a phenotype other than basal-like.

6. The method of claim 1, which further comprises administering to the patient an effective amount of at least one additional anti-cancer agent.

7. The method of claim 6, wherein the at least one additional anti-cancer agent is selected from the group consisting of platinum-based chemotherapy drugs, taxanes, tyrosine kinase inhibitors, anti-EGFR antibodies, anti-ErbB2 antibodies, and combinations thereof.

8. The method of claim 7, wherein the at least one additional anti-cancer agent is a taxane and the taxane is paclitaxel.

9. The method of claim 6, wherein the at least one additional anti-cancer agent comprises an EGFR inhibitor.

10. The method of claim 9, wherein the EGFR inhibitor comprises an anti-EGFR antibody.

11. The method of claim 10, wherein the anti-EGFR antibody is selected from the group consisting of cetuximab, matuzumab, panitumumab, nimotuzumab and mAb 806.

12. The method of claim 9, wherein the EGFR inhibitor is a small molecule inhibitor of EGFR signaling selected from the group consisting of gefitinib, lapatinib, canertinib, pelitinib, and erlotinib HCL.

13. The method of claim 6, wherein the at least one additional anti-cancer agent comprises a VEGF inhibitor.

14. The method of claim 13, wherein the VEGF inhibitor comprises bevacizumab.

15. The method of claim 1, wherein the triple negative breast cancer tumor is a tumor which scores negative for estrogen receptor (ER) and progesterone receptor and yields a test result of 0, 1+, or 2+ using a semi-quantitative immunohistochemical assay using a polyclonal anti-HER2 primary antibody.

16. The method of claim 15, wherein the tumor is FISH negative for HER2 gene amplification.

17. A method of treating triple negative breast cancer which expresses ErbB3, the method comprising: identifying a patient with a basal-like breast cancer tumor; and administering to the identified patient an effective amount of an anti-cancer agent comprising an anti-ErbB3 antibody that comprises, in amino terminal to carboxy terminal order, a V.sub.H CDR1 sequence as shown in SEQ ID NO:3, a V.sub.H CDR2 sequence as shown in SEQ ID NO:4 and a V.sub.H CDR3 sequence as shown in SEQ ID NO:5, and, in amino terminal to carboxy terminal order, a V.sub.L CDR1 sequence as shown in SEQ ID NO:6, a V.sub.L CDR2 sequence as shown in SEQ ID NO:7 and a V.sub.L CDR3 sequence as shown in SEQ ID NO:8.

18. The method of claim 17, wherein the administration of the effective amount of the anti-cancer agent suppresses growth of the basal-like breast cancer tumor.

19. The method of claim 17, which further comprises administering to the patient an effective amount of at least one additional anti-cancer agent.

20. The method of claim 19, wherein the at least one additional anti-cancer agent is paclitaxel.

Details for Patent 8,895,001

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2030-03-11
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 ⤷  Try a Trial 2030-03-11
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2030-03-11
Amgen, Inc. VECTIBIX panitumumab Injection 125147 09/27/2006 ⤷  Try a Trial 2030-03-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.